Cellceutix Corporation

cellceutix is an emerging bio-pharmaceutical company
focusing in the areas of cancer
and inflammatory disease...

Press Release 11/7/2011

Cellceutix Files Investigational New Drug Application (IND) with FDA, Clinical Trials Planned at Dana-Farber/Harvard Cancer Center

Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the "Guardian Angel of the Human Genome"

Cellceutix announced that research on KevetrinTM, the Company's flagship compound against cancers, has demonstrated the potential for a major breakthrough in cancer research by exhibiting an activation of p53 in both wild and mutant types of p53. p53, often referred to as the "Guardian Angel Gene" or the "Guardian Angel of the Human Genome" due its crucial role in controlling cell mutations, is a tumor suppressor protein that is encoded by the TP53 gene in humans and has been widely regarded as possibly holding a key to the future of cancer therapies.

p53 has been shown to play critical roles in the homeostatic health of the human body by activating proteins required to repair DNA and plays a major role in the life cycle of cells by inducing cell cycle arrest and apoptosis to maintain cellular and genetic stability.

In more than 50 percent of all human carcinomas, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are greater than 10 million people with tumors that contain inactivated p53, while a similar number have tumors in which the p53 pathway is partially abrogated by inactivation of other signaling components. This has left cancer researchers with the grand challenge of searching for therapies that could restore the protein's protective function, which Kevetrin appears to be doing the majority of the time.

Extensive pre-clinical research on Kevetrin has resulted in a compilation of promising data showing a wide therapeutic index through the re-activation of p53. Importantly, Kevetrin has been proven to be non-genotoxic (does not damage DNA). Research has shown Kevetrin to outperform current chemotherapies in testing against multiple cancer lines, including breast, lung, head and neck, colon, prostate, pancreatic and leukemia. Cellceutix has planned clinical trials for Kevetrin at the world’s most prominent cancer research center.

April 1, 2012 : PDF : AACR Poster Presented by Cellceutix - Kevetrin™ targets targets both MDM2 both MDM2-p53 p53 and Rb and Rb-E2F E2F pathways in tumor suppression

April 11, 2011 : PDF: AACR Poster Presented by Cellceutix - Kevetrin™ - A Novel Small Molecule, Activates p53, Enhances Expression of p21, Induces Cell Cycle Arrest and Apoptosis in a Human Cancer Cell Line

American Association for Cancer Research (AACR) Debuts Frontiers in Basic Cancer Research Meeting

"Scientists at Cellceutix Corporation may have developed a new compound that could significantly delay lung tumor growth, according to data presented at the AACR Frontiers in Basic Cancer Research Meeting."

full article: http://www.aacr.org/home/public--media/aacr-press-releases.aspx?d=1584

Kevetrin^TM Demonstrates Significant Delay of Tumor Growth in Drug Resistant Breast Cancer

Kevetrin^TM Animal Model Testing Success Against Multi-Drug Resistant Lung Cancer

Cellceutix Compund KM-133 Shows Significant Effect On Psoriasis

http://www.aacr.org/home/public--media/aacr-press-releases.aspx?d=1584

Syracuse Basketball Icon Jim Boeheim Joins Cellceutix to Fight Cancer

The Best Is Yet To Come

Thank you for visiting Cellceutix Corporation's official website. My name is Leo Ehrlich,CPA Chief Executive Officer of Cellceutix. There are a great many things happening at our Company. Our most recent announcement concerned our flagship anti-cancer compound, Kevetrin, which reactivates p53, the “Guardian Angel of the Human Genome.” Potentially, this is not only a major breakthrough for Cellceutix, but for the world of oncology, as p53 has long been believed to possibly hold a key to unlocking the next generation of cancer therapies. p53 has a deserved nickname as it functions to activate the life-saving actions of other proteins within our bodies. In more than 50% of all cancers, p53 is mutated and not performing properly to help protection of our cells, allowing various malignancies the opportunity to rapidly grow and multiply. Kevetrin has been shown to reactivate P53, often to baseline status, which, in turn, activates other proteins that destroy or significantly slow the growth of cancer cells. This is something that scientists worldwide, at pharmaceutical companies both large and small, have been striving for, but to the best of our knowledge, have not yet achieved.

Continue Reading..